The effect of generic drugs in treatment of chronic hepatitis C patients
Not Applicable
- Conditions
- Chronic viral hepatitis C.Chronic viral hepatitis C
- Registration Number
- IRCT2017020210417N6
- Lead Sponsor
- Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Being diagnosed with hepatitis C and having a detectable viral count; Having not received any medications yet or being unresponsive to previous interferon-based treatments; Providing a freely signed consent form to be treated with new generic medications.
Exclusion criteria :Having a renal failure defined as eGFR
< 30 mL/min; Having a very advanced liver disease defined as MELD score > 20 or Child-Pugh score
> 12; Heart rate < 50 beats/min; History of previous treatment failure with sofosbuvir-based regimen; History of taking amiodarone within the last 6 months; Not consenting to participate in the study.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hepatitis C viral load. Timepoint: Beginig of treatment- one month after the begining of treatment- The end of treatment-Three months after the end of treatment. Method of measurement: Using Real Time PCR.;Hepatitis C virus genotype. Timepoint: at the beginning of treatment. Method of measurement: using gene sequencing.
- Secondary Outcome Measures
Name Time Method Alanin amino transferase (ALT). Timepoint: At the beginning of treatment, then monthly for three months after the end of treatment. Method of measurement: Enzyme serum level.